Data from KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations Article Swipe

View

Xiaoni Liu , Shang‐Min Zhang , Meaghan K. McGeary , Irina Krykbaeva , Ling‐Ping Lai , Daniel J. Jansen , Stephen C. Kales , Anton Simeonov , Matthew D. Hall , Daniel P. Kelly , Marcus Bosenberg , Qin Yan ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/1535-7163.c.6538539.v1

Tumor heterogeneity is a major challenge for cancer treatment, especially due to the presence of various subpopulations with stem cell or progenitor cell properties. In mouse melanomas, both CD34⁺p75⁻ (CD34⁺) and CD34⁻p75⁻ (CD34⁻) tumor subpopulations were characterized as melanoma-propagating cells (MPC) that exhibit some of those key features. However, these two subpopulations differ from each other in tumorigenic potential, ability to recapitulate heterogeneity, and chemoresistance. In this study, we demonstrate that CD34⁺ and CD34⁻ subpopulations carrying the BRAF^V600E mutation confer differential sensitivity to targeted BRAF inhibition. Through elevated KDM5B expression, melanoma cells shift toward a more drug-tolerant, CD34⁻ state upon exposure to BRAF inhibitor or combined BRAF inhibitor and MEK inhibitor treatment. KDM5B loss or inhibition shifts melanoma cells to the more BRAF inhibitor–sensitive CD34⁺ state. These results support that KDM5B is a critical epigenetic regulator that governs the transition of key MPC subpopulations with distinct drug sensitivity. This study also emphasizes the importance of continuing to advance our understanding of intratumor heterogeneity and ultimately develop novel therapeutics by altering the heterogeneous characteristics of melanoma.

Related Topics

Concepts

Melanoma Molecular biology Cancer research Chemistry Biology

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1535-7163.c.6538539.v1
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4362493139

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4362493139

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1535-7163.c.6538539.v1

Digital Object Identifier
Title: Data from KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-04-03

Full publication date if available
Authors: Xiaoni Liu, Shang‐Min Zhang, Meaghan K. McGeary, Irina Krykbaeva, Ling‐Ping Lai, Daniel J. Jansen, Stephen C. Kales, Anton Simeonov, Matthew D. Hall, Daniel P. Kelly, Marcus Bosenberg, Qin Yan

List of authors in order
Landing page: https://doi.org/10.1158/1535-7163.c.6538539.v1

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1535-7163.c.6538539.v1

Direct OA link when available
Concepts: Melanoma, Molecular biology, Cancer research, Chemistry, Biology

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4362493139
doi	https://doi.org/10.1158/1535-7163.c.6538539.v1
ids.doi	https://doi.org/10.1158/1535-7163.c.6538539.v1
ids.openalex	https://openalex.org/W4362493139
fwci	0.0
type	preprint
title	Data from KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11533
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9994999766349792
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1312
topics[0].subfield.display_name	Molecular Biology
topics[0].display_name	Melanoma and MAPK Pathways
topics[1].id	https://openalex.org/T11736
topics[1].field.id	https://openalex.org/fields/13
topics[1].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[1].score	0.9951000213623047
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/1312
topics[1].subfield.display_name	Molecular Biology
topics[1].display_name	Histone Deacetylase Inhibitors Research
topics[2].id	https://openalex.org/T12534
topics[2].field.id	https://openalex.org/fields/13
topics[2].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[2].score	0.9945999979972839
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/1312
topics[2].subfield.display_name	Molecular Biology
topics[2].display_name	Protein Degradation and Inhibitors
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2777658100
concepts[0].level	2
concepts[0].score	0.526386022567749
concepts[0].wikidata	https://www.wikidata.org/wiki/Q180614
concepts[0].display_name	Melanoma
concepts[1].id	https://openalex.org/C153911025
concepts[1].level	1
concepts[1].score	0.5240110158920288
concepts[1].wikidata	https://www.wikidata.org/wiki/Q7202
concepts[1].display_name	Molecular biology
concepts[2].id	https://openalex.org/C502942594
concepts[2].level	1
concepts[2].score	0.5229666829109192
concepts[2].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[2].display_name	Cancer research
concepts[3].id	https://openalex.org/C185592680
concepts[3].level	0
concepts[3].score	0.4282546639442444
concepts[3].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[3].display_name	Chemistry
concepts[4].id	https://openalex.org/C86803240
concepts[4].level	0
concepts[4].score	0.37888744473457336
concepts[4].wikidata	https://www.wikidata.org/wiki/Q420
concepts[4].display_name	Biology
keywords[0].id	https://openalex.org/keywords/melanoma
keywords[0].score	0.526386022567749
keywords[0].display_name	Melanoma
keywords[1].id	https://openalex.org/keywords/molecular-biology
keywords[1].score	0.5240110158920288
keywords[1].display_name	Molecular biology
keywords[2].id	https://openalex.org/keywords/cancer-research
keywords[2].score	0.5229666829109192
keywords[2].display_name	Cancer research
keywords[3].id	https://openalex.org/keywords/chemistry
keywords[3].score	0.4282546639442444
keywords[3].display_name	Chemistry
keywords[4].id	https://openalex.org/keywords/biology
keywords[4].score	0.37888744473457336
keywords[4].display_name	Biology
language	en
locations[0].id	doi:10.1158/1535-7163.c.6538539.v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1535-7163.c.6538539.v1
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5101772463
authorships[0].author.orcid	https://orcid.org/0000-0002-8547-3290
authorships[0].author.display_name	Xiaoni Liu
authorships[0].author_position	first
authorships[0].raw_author_name	Xiaoni Liu
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5054378091
authorships[1].author.orcid
authorships[1].author.display_name	Shang‐Min Zhang
authorships[1].author_position	middle
authorships[1].raw_author_name	Shang-Min Zhang
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5033210107
authorships[2].author.orcid	https://orcid.org/0000-0002-8505-7158
authorships[2].author.display_name	Meaghan K. McGeary
authorships[2].author_position	middle
authorships[2].raw_author_name	Meaghan K. McGeary
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5065997645
authorships[3].author.orcid	https://orcid.org/0000-0003-1380-7607
authorships[3].author.display_name	Irina Krykbaeva
authorships[3].author_position	middle
authorships[3].raw_author_name	Irina Krykbaeva
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5038251894
authorships[4].author.orcid	https://orcid.org/0000-0002-9651-7420
authorships[4].author.display_name	Ling‐Ping Lai
authorships[4].author_position	middle
authorships[4].raw_author_name	Ling Lai
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5042598414
authorships[5].author.orcid
authorships[5].author.display_name	Daniel J. Jansen
authorships[5].author_position	middle
authorships[5].raw_author_name	Daniel J. Jansen
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5035466128
authorships[6].author.orcid	https://orcid.org/0000-0002-8702-5766
authorships[6].author.display_name	Stephen C. Kales
authorships[6].author_position	middle
authorships[6].raw_author_name	Stephen C. Kales
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5059969497
authorships[7].author.orcid	https://orcid.org/0000-0002-4523-9977
authorships[7].author.display_name	Anton Simeonov
authorships[7].author_position	middle
authorships[7].raw_author_name	Anton Simeonov
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5022924056
authorships[8].author.orcid	https://orcid.org/0000-0002-5073-442X
authorships[8].author.display_name	Matthew D. Hall
authorships[8].author_position	middle
authorships[8].raw_author_name	Matthew D. Hall
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5028299159
authorships[9].author.orcid	https://orcid.org/0000-0002-3811-9491
authorships[9].author.display_name	Daniel P. Kelly
authorships[9].author_position	middle
authorships[9].raw_author_name	Daniel P. Kelly
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5076813249
authorships[10].author.orcid	https://orcid.org/0000-0003-0166-1612
authorships[10].author.display_name	Marcus Bosenberg
authorships[10].author_position	middle
authorships[10].raw_author_name	Marcus W. Bosenberg
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5100510256
authorships[11].author.orcid	https://orcid.org/0009-0001-7857-2653
authorships[11].author.display_name	Qin Yan
authorships[11].author_position	last
authorships[11].raw_author_name	Qin Yan
authorships[11].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1535-7163.c.6538539.v1
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Data from KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11533
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9994999766349792
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1312
primary_topic.subfield.display_name	Molecular Biology
primary_topic.display_name	Melanoma and MAPK Pathways
related_works	https://openalex.org/W4387497383, https://openalex.org/W2948807893, https://openalex.org/W2778153218, https://openalex.org/W2748952813, https://openalex.org/W1531601525, https://openalex.org/W4391375266, https://openalex.org/W2078814861, https://openalex.org/W2527526854, https://openalex.org/W2592449238, https://openalex.org/W3112004363
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1535-7163.c.6538539.v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1535-7163.c.6538539.v1
primary_location.id	doi:10.1158/1535-7163.c.6538539.v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1535-7163.c.6538539.v1
publication_date	2023-04-03
publication_year	2023
referenced_works_count	0
abstract_inverted_index.a	3, 94, 132
abstract_inverted_index.In	24, 65
abstract_inverted_index.as	37
abstract_inverted_index.by	168
abstract_inverted_index.in	56
abstract_inverted_index.is	2, 131
abstract_inverted_index.of	14, 44, 140, 154, 160, 173
abstract_inverted_index.or	20, 104, 114
abstract_inverted_index.to	11, 60, 82, 101, 119, 156
abstract_inverted_index.we	68
abstract_inverted_index.MEK	109
abstract_inverted_index.MPC	142
abstract_inverted_index.and	30, 63, 72, 108, 163
abstract_inverted_index.due	10
abstract_inverted_index.for	6
abstract_inverted_index.key	46, 141
abstract_inverted_index.our	158
abstract_inverted_index.the	12, 76, 120, 138, 152, 170
abstract_inverted_index.two	50
abstract_inverted_index.BRAF	84, 102, 106, 122
abstract_inverted_index.This	148
abstract_inverted_index.also	150
abstract_inverted_index.both	27
abstract_inverted_index.cell	19, 22
abstract_inverted_index.drug	146
abstract_inverted_index.each	54
abstract_inverted_index.from	53
abstract_inverted_index.loss	113
abstract_inverted_index.more	95, 121
abstract_inverted_index.some	43
abstract_inverted_index.stem	18
abstract_inverted_index.that	41, 70, 129, 136
abstract_inverted_index.this	66
abstract_inverted_index.upon	99
abstract_inverted_index.were	35
abstract_inverted_index.with	17, 144
abstract_inverted_index.(MPC)	40
abstract_inverted_index.KDM5B	88, 112, 130
abstract_inverted_index.These	126
abstract_inverted_index.cells	39, 91, 118
abstract_inverted_index.major	4
abstract_inverted_index.mouse	25
abstract_inverted_index.novel	166
abstract_inverted_index.other	55
abstract_inverted_index.shift	92
abstract_inverted_index.state	98
abstract_inverted_index.study	149
abstract_inverted_index.these	49
abstract_inverted_index.those	45
abstract_inverted_index.tumor	33
abstract_inverted_index.cancer	7
abstract_inverted_index.confer	79
abstract_inverted_index.differ	52
abstract_inverted_index.shifts	116
abstract_inverted_index.state.	125
abstract_inverted_index.study,	67
abstract_inverted_index.toward	93
abstract_inverted_index.Through	86
abstract_inverted_index.ability	59
abstract_inverted_index.advance	157
abstract_inverted_index.develop	165
abstract_inverted_index.exhibit	42
abstract_inverted_index.governs	137
abstract_inverted_index.results	127
abstract_inverted_index.support	128
abstract_inverted_index.various	15
abstract_inverted_index.However,	48
abstract_inverted_index.altering	169
abstract_inverted_index.carrying	75
abstract_inverted_index.combined	105
abstract_inverted_index.critical	133
abstract_inverted_index.distinct	145
abstract_inverted_index.elevated	87
abstract_inverted_index.exposure	100
abstract_inverted_index.melanoma	90, 117
abstract_inverted_index.mutation	78
abstract_inverted_index.presence	13
abstract_inverted_index.targeted	83
abstract_inverted_index.challenge	5
abstract_inverted_index.features.	47
abstract_inverted_index.inhibitor	103, 107, 110
abstract_inverted_index.regulator	135
abstract_inverted_index.continuing	155
abstract_inverted_index.emphasizes	151
abstract_inverted_index.epigenetic	134
abstract_inverted_index.especially	9
abstract_inverted_index.importance	153
abstract_inverted_index.inhibition	115
abstract_inverted_index.intratumor	161
abstract_inverted_index.melanomas,	26
abstract_inverted_index.potential,	58
abstract_inverted_index.progenitor	21
abstract_inverted_index.transition	139
abstract_inverted_index.treatment,	8
abstract_inverted_index.treatment.	111
abstract_inverted_index.ultimately	164
abstract_inverted_index.demonstrate	69
abstract_inverted_index.expression,	89
abstract_inverted_index.inhibition.	85
abstract_inverted_index.properties.	23
abstract_inverted_index.sensitivity	81
abstract_inverted_index.tumorigenic	57
abstract_inverted_index.differential	80
abstract_inverted_index.recapitulate	61
abstract_inverted_index.sensitivity.	147
abstract_inverted_index.therapeutics	167
abstract_inverted_index.characterized	36
abstract_inverted_index.heterogeneity	1, 162
abstract_inverted_index.heterogeneous	171
abstract_inverted_index.understanding	159
abstract_inverted_index.drug-tolerant,	96
abstract_inverted_index.heterogeneity,	62
abstract_inverted_index.subpopulations	16, 34, 51, 74, 143
abstract_inverted_index.characteristics	172
abstract_inverted_index.chemoresistance.	64
abstract_inverted_index.melanoma-propagating	38
abstract_inverted_index.inhibitor–sensitive	123
abstract_inverted_index.CD34<sup>+</sup>	71, 124
abstract_inverted_index.(CD34<sup>+</sup>)	29
abstract_inverted_index.CD34<sup>−</sup>	73, 97
abstract_inverted_index.melanoma.</p></div>	174
abstract_inverted_index.(CD34<sup>−</sup>)	32
abstract_inverted_index.<div>Abstract<p>Tumor	0
abstract_inverted_index.<i>BRAF<sup>V600E</sup></i>	77
abstract_inverted_index.CD34<sup>+</sup>p75<sup>−</sup>	28
abstract_inverted_index.CD34<sup>−</sup>p75<sup>−</sup>	31
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	12
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.8899999856948853
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.17410763
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False